SPIA
CRSP icon

Steward Partners Investment Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Steward Partners Investment Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Sell
2,673
-380
-12% -$20K ﹤0.01% 2247
2025
Q4 		$160K Buy
3,053
+292
+11% +$17.5K ﹤0.01% 2039
2025
Q3 		$179K Buy
2,761
+769
+39% +$44.1K ﹤0.01% 1928
2025
Q2 		$96.9K Buy
1,992
+552
+38% +$21.4K ﹤0.01% 2134
2025
Q1 		$49K Buy
1,440
+579
+67% +$24.5K ﹤0.01% 2389
2024
Q4 		$33.9K Sell
861
-87
-9% -$4.11K ﹤0.01% 2539
2024
Q3 		$44.5K Sell
948
-191
-17% -$9.69K ﹤0.01% 2287
2024
Q2 		$61.5K Sell
1,139
-403
-26% -$23.3K ﹤0.01% 2001
2024
Q1 		$105K Sell
1,542
-460
-23% -$32.9K ﹤0.01% 1743
2023
Q4 		$125K Buy
2,002
+18
+0.9% +$995 ﹤0.01% 1582
2023
Q3 		$90.1K Buy
1,984
+31
+2% +$1.6K ﹤0.01% 1631
2023
Q2 		$110K Sell
1,953
-35
-2% -$1.99K ﹤0.01% 1546
2023
Q1 		$89.9K Sell
1,988
-20
-1% -$971 ﹤0.01% 1631
2022
Q4 		$81.6K Buy
2,008
+95
+5% +$5.04K ﹤0.01% 1626
2022
Q3 		$125K Sell
1,913
-31
-2% -$2.25K ﹤0.01% 1401
2022
Q2 		$118K Buy
1,944
+148
+8% +$8.7K ﹤0.01% 1432
2022
Q1 		$113K Buy
1,796
+1,093
+155% +$68.6K ﹤0.01% 1556
2021
Q4 		$53K Sell
703
-348
-33% -$30.4K ﹤0.01% 1875
2021
Q3 		$118K Sell
1,051
-719
-41% -$90.3K ﹤0.01% 1480
2021
Q2 		$287K Sell
1,770
-2,384
-57% -$290K ﹤0.01% 1212
2021
Q1 		$506K Buy
4,154
+3,237
+353% +$489K 0.01% 884
2020
Q4 		$140K Buy
917
+544
+146% +$64.3K ﹤0.01% 1219
2020
Q3 		$31K Buy
373
+73
+24% +$6.47K ﹤0.01% 1708
2020
Q2 		$22K Hold
300
– – ﹤0.01% 1728
2020
Q1 		$12K Hold
300
– – ﹤0.01% 1780
2019
Q4 		$18K Hold
300
– – ﹤0.01% 1800
2019
Q3 		$12K Hold
300
– – ﹤0.01% 1902
2019
Q2 		$14K Buy
+300
New +$12K ﹤0.01% 1829
2018
Q4 		– Sell
-300
Closed -$13K – 1029
2018
Q3 		$13K Buy
300
+200
+200% +$10.5K ﹤0.01% 1756
2018
Q2 		$6K Hold
100
– – ﹤0.01% 1920
2018
Q1 		$4K Buy
+100
New +$4.13K ﹤0.01% 1837

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Steward Partners Investment Advisory's CRSP Position: Q1 2026 in Review

Steward Partners Investment Advisory reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q1 2026, selling an estimated $20K and leaving 2,673 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #2247.

Steward Partners Investment Advisory first reported a position in CRSP in Q1 2018 and has held it in 31 quarters since. The position peaked at $506K in Q1 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Steward Partners Investment Advisory held 2,673 shares of CRISPR Therapeutics worth $127K as of Q1 2026.
  • Steward Partners Investment Advisory sold 380 CRISPR Therapeutics shares in Q1 2026, an estimated $20K.
  • CRISPR Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #2247 holding.
  • Steward Partners Investment Advisory first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 31 quarters since.
  • Steward Partners Investment Advisory's CRISPR Therapeutics position peaked at $506K in Q1 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.